Where Alnylam Pharmaceuticals Stands With Analysts
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $256
Oppenheimer analyst Leland Gershell maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform and raises the price target from $170 to $256.
BMO Capital Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $200
BMO Capital analyst Gary Nachman maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $192 to $200.
Important Biotech Catalysts For September 8, 2022 – End Of The Day Summary
The United States Food and Drug Administration (FDA) has approved Revance Therapeutics’ (NASDAQ:RVNC) lead asset DAXXIFY (DaxibotulinumtoxinA-lanm) for…
Alnylam Shares Detailed Patisiran Data From Rare Disease Study
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Alnylam Announced APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Met Primary Endpoint, First Secondary Endpoint
Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY) today announced positive results from the APOLLO-B Phase 3 study of patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN). Cemdisiran is an…
Alnylam Reports Results From Phase 2 Study Of Investigational Cemdisiran For The Treatment Of IgA Nephropathy; Co Reports ‘Cemdisiran Was Generally Well-Tolerated in Patients with IgA Nephropathy’
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) today announced positive results from a Phase 2 study of cemdisiran, an investigational RNAi therapeutic targeting the C5 component of the complement pathway, in development in
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has
Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart?
If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.